 |
18 Diseases |  |
22 Trials |
|
22 Trials |  |
2501 News |  |
| «12...10111213141516171819202122» |
- | Sovaldi (sofosbuvir) / Gilead
@GileadSciences jacks up the price of #sofosbuvir in #Brazil after the patent was granted... https://t.co/uPHem73Hcc (Twitter) - Oct 22, 2019
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Management Of Patients With Hepatitis B Virus Reactivation Post-DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV-HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis. (Pubmed Central) - Oct 22, 2019
They treated with sofosbuvir 400 mg and daklatasvir 60 mg once daily for 3 months...Regarding patients with HBV reactivation, at 12 months posttreatment they showed significant decreases in liver enzymes, bilirubin, and INR, with increased platelet count (P=0.001), each with undetectable HBV PCR (P=0.001). HBV-HCV coinfected patients with no/mild hepatic fibrosis, HBeAg seroconversion, and HBV DNA <2,000 IU/mL can complete direct-acting antiviral therapy without HBV antiviral treatment with close monitoring.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, P3 data, Journal: Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. (Pubmed Central) - Oct 14, 2019
HBV-HCV coinfected patients with no/mild hepatic fibrosis, HBeAg seroconversion, and HBV DNA <2,000 IU/mL can complete direct-acting antiviral therapy without HBV antiviral treatment with close monitoring. No abstract available
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Efficacy and Tolerability of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C Genotype 3 in Patients Undergoing Maintenance Hemodialysis (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4362;
Overall 29/32 (90.62%) patients achieved SVR (group 1= 15/15 or 100%; group 2= 14/17 or 82.35%).Three patients in group 2 who did not achieved SVR were all infected by genotype 1 and two of them had previously received treatment with interferon. Conclusion DAA therapy using sofosbuvir and declatsavir is highly effective and tolerable in patients with HCV genotype 3 undergoing maintenance hemodialysis, especially when given daily.Decreasing the dose or frequency of SOF may lead to decreased SVR or higher relapses.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. (Pubmed Central) - Oct 11, 2019
Natural RASs are common in Italian patients infected with HCV-GTs 1-4. High prevalence of clinically-relevant RASs (such as Y93H) supports the appropriateness of HCV resistance-test to properly guide DAA-based therapy.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
New trial: the Pulmonary Safety of Antihepatitis C Treatment (clinicaltrials.gov) - Oct 9, 2019
P, N=50, Not yet recruiting, Sponsor: Assiut University
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: HCV phylogenetic Signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. (Pubmed Central) - Oct 8, 2019
High prevalence of clinically-relevant RASs (such as Y93H) supports the appropriateness of HCV resistance-test to properly guide DAA-based therapy. Differences in the prevalence of GT2 and GT3 subtypes and NS5A RAS were observed between Asian and Western countries.
- | velpatasvir (GS-5816) / Gilead, Sovaldi (sofosbuvir) / Gilead
Journal: Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet. (Pubmed Central) - Oct 5, 2019
The results show that comparing the performance of the two utilized columns revealed that shorter column (2.1 mm × 100 mm) with small particle packing was superior to the longer column (4.6 × 150 mm) for the analysis of the studied drugs allowing a reduction of the analysis time by 70% without any detrimental effect on performance. This prompts the decrease of the investigation costs by saving money on organic solvents and expanding the overall number of analyses per day.
- | AT-527 / Atea Pharma, Roche, Sovaldi (sofosbuvir) / Gilead
Clinical, PK/PD data, Journal: Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. (Pubmed Central) - Oct 3, 2019
Exposure-antiviral response analysis identified 550 mg (free base equivalent) as the optimal dose of AT-527. Safety and antiviral activity data from this study warrant continued clinical development of AT-527 dosed once daily.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. (Pubmed Central) - Oct 3, 2019
To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols.
- | voxilaprevir (GS-9857) / Gilead, Sovaldi (sofosbuvir) / Gilead
Journal: Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. (Pubmed Central) - Oct 3, 2019
For example, D168E, highly resistanct to all protease inhibitors except voxilaprevir, was nearly absent in all subtypes except in 43.48% of GT5a sequences...A150V in GT3a, associated with sofosbuvir treatment failure, was most prevalent in Asia (44.09%), followed by Europe (31.19%), Oceania (24.29%), and North America (19.05%)...Considering the specific RASs prevalence will help the clinicians to make optimal treatment choices. The RASs pairs would benefit anti-HCV drug development.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. (Pubmed Central) - Oct 2, 2019
Fibrosis regression (TE, APRI and FIB 4) was detected with direct-acting agents and interferon-based therapy. Treated patients with significant fibrosis will benefit of fibrosis regression irrespective to their treatment response, whereas fibrosis regression was associated with SVR in cirrhotic patients.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, Sovaldi (sofosbuvir) / Gilead
Clinical, P2 data, Journal: Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials. (Pubmed Central) - Oct 2, 2019
Among the 22 patients experiencing VF, treatment-emergent substitutions were detected in NS3 in 50% and in NS5A in 82% of patients, frequently as a combination of substitutions that conferred resistance to glecaprevir and/or pibrentasvir. The glecaprevir/pibrentasvir regimen, when using the recommended durations, allows for a pangenotypic treatment option without the need for baseline resistance testing.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, PK/PD data, Journal: Pharmacokinetics, Safety, and Tolerability of the Direct-Acting Hepatitis C Antiviral Sofosbuvir in Healthy Chinese Subjects. (Pubmed Central) - Oct 2, 2019
The pharmacokinetic properties of sofosbuvir, GS-556500, and GS-311007 were found to be broadly similar in healthy Chinese subjects compared with non-Chinese subjects in previous sofosbuvir studies. ChinaDrugTrials.org.cn identifier: CTR20150249.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission. (Pubmed Central) - Oct 2, 2019
ChinaDrugTrials.org.cn identifier: CTR20150249. No abstract available
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. (Pubmed Central) - Oct 2, 2019
Here we present case reports of successful sofosbuvir based treatment in patients with advanced class B cirrhosis with prior PEG-IFN/ribavirin and all-oral DAA failure with multiclass drug resistance. HCV resistance testing at failure was performed to guide the choice of salvage therapy.
- | seraprevir (GP-205) / GinkgoPharma
New P2a trial, Combination therapy: Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients (clinicaltrials.gov) - Sep 30, 2019
P2a, N=36, Recruiting, Sponsor: Ginkgopharma CO., LTD
- Sovaldi (sofosbuvir) / Gilead
COURSE OF CIRRHOSIS REGRESSION: LESSONS FROM PATIENTS WITH HCV CIRRHOSIS FOLLOWING SUCCESSFUL SOFOSBUVIR-BASED TREATMENT (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2614;
P=N/A
In patients with cirrhosis in whom HCV has been eradicated by SOF-based therapy, NITs suggest significant fibrosis improvement in 25-50% of patients within several years of followup. Associations between reductions in these NITs and improvements in clinical outcomes require evaluation during longer-term follow-up
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
DETECTION OF OCCULT HEPATITIS C VIRUS INFECTION IN EGYPTIAN PATIENTS WHO ACHIEVED A SUSTAINED VIROLOGIC RESPONSE TO DIRECT-ACTING ANTIVIRAL AGENTS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2558;
Occult HCV is present in a minority of patients with significant fibrosis (F3- F4) who achieved an SVR 12 – 24 weeks . Monitoring and follow up of those patient is mandatory to assess their future outcome.
- Zepatier (grazoprevir/elbasvir) / Merck (MSD), tacrolimus / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR ± SOFOSBUVIR IN POST SOLID ORGAN TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2434;
Elbasvir and Grazoprevir (± sofosbuvir) is effective and safe in post-transplant population. Serum trough concentrations of tacrolimus does not seem to have been largely affected.
- AT-527 / Atea Pharma, Sovaldi (sofosbuvir) / Gilead
HCV VIRAL KINETIC ANALYSIS PREDICTS SHORTER TREATMENT DURATION WITH AT-527, A PURINE NUCLEOTIDE PRODRUG WITH POTENT PAN-GENOTYPIC ANTIVIRAL ACTIVITY IN HCV-INFECTED SUBJECTS REGARDLESS OF CIRRHOSIS STATUS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2159;
Viral kinetic analysis based on data generated from a 7-day dosing of AT-527 as a single agent suggests that >90% of all patients should be cured with 8 wks of treatment. When combined with a potent pan-genotypic NS5A inhibitor, higher cure rates are anticipated and further shortening of treatment duration may be possible.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
HEPATITIS C TREATMENT AMONG HCV-HIV CO-INFECTED PATIENTS IN BRAZIL: A MULTICENTER STUDY ON BASELINE RESISTANCE ANALYSES AND SUSTAINED VIROLOGIC RESPONSE RATE (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2095;
RASs were not frequent and did not impact on SVR rate. And finally, our data highlights the need for caution with the use of concurrent anticonvulsant drugs and DAAs since the latter seem to decrease the chances of achieving SVR.
- HISTOLOGICAL AND SVR DATA ON HCV + GRAFT TO HCV NEGATIVE LIVER TRANSPLANT RECIPIENTS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2031;
2. All patients with HCV Viremia achieved SVR with treatment.
- Sovaldi (sofosbuvir) / Gilead
IMPACT OF LIVER STIFFNESS EVOLUTION ON RESIDUAL RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITS C PATIENTS AFTER VIRAL ERADICATION (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1951;
At one-year post SVR, LSM<10kPa seems associated to an insignificant risk for HCC development. Depending on the local resources, interruption of HCC screening should be discussed among these patients.
- Sovaldi (sofosbuvir) / Gilead
INNOVATIVE PROCEDURES FOR MICRO-ELIMINATION OF HCV INFECTION IN A HIGH-RISK POPULATION OF UNDOCUMENTED MIGRANTS AND LOW-INCOME REFUGEES (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1858;
HCV-RNA positive patients were treated with sofosbuvir plus velpatasvir +ribavirin for 12 weeks and followed up untreated for 12 weeks after treatment withdrawal Of the 2,698 migrants observed in the study period, 2,563 (95%) accepted to be screened. This innovative procedures for micro-elimination of HCV infection seems to be effective in undocumented migrants and low-income refugees with rates of diagnosis, linkage to care and cure in line with the WHO goals
- Sovaldi (sofosbuvir) / Gilead
INTEGRATED COMMUNITY-BASED HCV SERVICE FOR PEOPLE WHO INJECT DRUGS (PROJECT ITTREAT): SVR12 RATES, HEALTH RELATED QUALITY OF LIFE AND COST OF HCV DETECTION AND CURE (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1851;
It also reports for the first time significant improvement in HRQoL after HCV cure in these vulnerable adults which can be achieved at modest costs. Our data makes a convincing case for community based integrated services for PWID to help pave the way for HCV elimination.
- coblopasvir (KW 136) / Beijing Kawin, Sovaldi (sofosbuvir) / Gilead
PAN-GENOTYPIC REGIMEN OF COBLOPASVIR PLUS SOFOSBUVIR FOR TREATMENT OF CHRONIC HEPATITIS C IN CHINA: A SINGLE-ARM, OPEN-LABEL, PHASE 3 TRIAL (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1427;
Our data makes a convincing case for community based integrated services for PWID to help pave the way for HCV elimination. The universal, pan-genotypic combination regimen of coblopasvir and sofosbuvir resulted in a high SVR and favorable safety profile in Chinese patients infected with HCV of GT-1, 2, 3 and 6, including those with advanced fibrosis or compensated cirrhosis.
- Sovaldi (sofosbuvir) / Gilead
PLASMA microRNA SIGNATURE OF IMMUNE DYSREGULATION IS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DIAGNOSIS POST HCV ANTIVIRAL THERAPY (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1320;
Plasma miR signatures may also act as biomarkers in identifying patients that are at risk for HCC development post DAA therapy. Additional work is needed to identify and confirm immune cell target effects of these miRs.
- PRECLINICAL DEVELOPMENT OF A FIRST-IN-CLASS FUSION INHIBITOR AGAINST DIVERSE AND MULTIDRUG-RESISTANT HCV STRAINS (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1291;
Time-of-addition experiments in cell-based infection and membrane fusion assays indicate that this compound targets the viral fusion step of the HCV life cycle. Fluoxazolevir is a promising fusion inhibitor for the next generation of combination drug cocktails for HCV treatment.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
PRELIMINARY RESULTS OF A NOVEL COMMUNITY-BASED MODEL OF HEPATITIS ELIMINATION IN AN UNDERSERVED AREA IN GUJRANWALA, PAKISTAN (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_1267;
Community outreach with involvement of local leadership and volunteers, deploying ECHO for tele-mentoring of providers, and access to free HCV testing and medication is a promising model for HCV elimination. National Hepatitis Elimination Strategies should consider supporting NGO’s working towards hepatitis elimination in high HCV prevalence regions.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
SUSTAINED VIROLOGICAL RESPONSE IN HCV INFECTED DECOMPENSATED CIRRHOTIC PATIENTS TREATED WITH DACLATASVIR AND SOFOSBUVIR (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_929;
This study showed Daclatasvir/ Sofosbuvir combination therapy is effective and safe in HCV infected decompensated cirrhotic patients without HCV genotyping. It can help HCV elimination in a resource constraint country like Myanmar.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
THE ROAD TO ELIMINATION OF HEPATITIS C: COSTS PER CURE FALL TO US $32 PER PERSON. (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_782;
API costs for DAAs continue to fall, and, consequently, potential generic prices fall too. National Health departments need to be aware of these potential costs when negotiating lower prices for mass HCV elimination programs.
- | Journal: Expert opinion on the management of renal manifestations of chronic HCV infection. (Pubmed Central) - Sep 28, 2019
In patients with severe kidney impairment, sofosbuvir-free regimens are preferred because sofosbuvir accumulation has been associated with a progressive worsening of renal function. In this Review, we provide our expert opinion on the current HCV treatment paradigm and highlight the remaining issues that need to be overcome to improve the treatment of HCV in this population.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. (Pubmed Central) - Sep 28, 2019
Clinically, infection with HCV G3 containing this variant reduces odds of SVR. In addition, we identified rare combinations of variants in HCV G3 that reduce response to sofosbuvir.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal, HEOR: Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. (Pubmed Central) - Sep 26, 2019
For each of the hepatitis C genotypes 1, 2 and 3, there were combinations of DAAs that were cost effective in a Norwegian setting. As a result of recent tender negotiations in Norway, treating all diagnosed patients with hepatitis C with the most cost-effective DAAs will result in lower total expenditure on these medications compared with 2015.
- | Sovaldi (sofosbuvir) / Gilead
Trial primary completion date: Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C (clinicaltrials.gov) - Sep 26, 2019
P=N/A, N=71, Active, not recruiting, Sponsor: University of Aarhus
As a result of recent tender negotiations in Norway, treating all diagnosed patients with hepatitis C with the most cost-effective DAAs will result in lower total expenditure on these medications compared with 2015. Trial primary completion date: Jan 2020 --> Jan 2019
- Tivicay (dolutegravir) / GSK, ViiV Healthcare, Sovaldi (sofosbuvir) / Gilead
RESOLUTION OF HEPATOPULMONARY SYNDROME WITH SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2754;
For her HCV, the patient was later started on a 12-week course of sofosbuvir, velpatasvir and ribavarin, which was confirmed to have eliminated her HCV infection at 24 weeks post-treatment...In conclusion this case report describes the successful reversal of HPS following the treatment of chronic HCV infection. These findings suggests that further research may discover a role for the use of DAAs in treatment of HPS.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. (Pubmed Central) - Sep 22, 2019
These findings suggests that further research may discover a role for the use of DAAs in treatment of HPS. G/P for 8 weeks in patients with chronic HCV GT1-6 infection without cirrhosis achieved a 98% overall SVR12 rate irrespective of baseline patient or viral characteristics; 4 additional weeks of treatment did not significantly increase the SVR12 rate, demonstrating that the optimal treatment duration in this population is 8 weeks.
- Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
TREATMENT WITH DIRECT-ACTING ANTIVIRALS DOES NEITHER INCREASE THE RISK OF HEPATOCELLULAR CARCINOMA PROGRESSION DURING WAITING LIST NOR RECURRENCE AFTER LIVER TRANSPLANTATION () - Sep 20, 2019 - Abstract #ILCA2019ILCA_156;
The most frequent genotype was 1b (28.7%), Sofosbuvir/ Daclatasvir was the most frequent DAAs regimen and overall sustained virological response was 89.8% (treated pre-LT 90.6% and post-LT 89.2%; P=0.78). The use of direct-acting antivirals for the treatment of HCV in patients with HCC listed for transplantation does not seem to be associated with an increased risk of tumor progression during the waiting list or recurrence after LT.
- | Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal, Real-World Evidence: Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. (Pubmed Central) - Sep 20, 2019
The use of direct-acting antivirals for the treatment of HCV in patients with HCC listed for transplantation does not seem to be associated with an increased risk of tumor progression during the waiting list or recurrence after LT. SOF/DCV with or without ribavirin is highly effective and safe for patients with genotype 2 HCV infection in real-world experience in Taiwan.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. (Pubmed Central) - Sep 19, 2019
SOF/DCV combined therapy could be used safely and effectively in the treatment of chronic HCV genotype-4 infection in leukemia/lymphoma treated children. No relapses were detected during treatment and throughout the follow up period for either the original malignant disease or the HCV infection.
- | carbamazepine / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Journal: Cytochrome P450 3A Induction Predicts P-glycoprotein Induction 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. (Pubmed Central) - Sep 18, 2019
The objective of this study was to determine if these relationships could be utilized to predict transporter induction by other CYP3A inducers (rifabutin and carbamazepine) and of another P-gp substrate, sofosbuvir...Carbamazepine induction of OATP was under-predicted, likely due to reported additional non-PXR agonism. Results demonstrate that the effect of a PXR agonist on CYP3A can be leveraged to inform on induction liability for other primarily PXR regulated P450s/transporters, allowing for prioritization of targeted DDI assessments during new drug development.
- | velpatasvir (GS-5816) / Gilead, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. (Pubmed Central) - Sep 18, 2019
Results demonstrate that the effect of a PXR agonist on CYP3A can be leveraged to inform on induction liability for other primarily PXR regulated P450s/transporters, allowing for prioritization of targeted DDI assessments during new drug development. Generic VEL/SOF-based therapy is well-tolerated and provides comparably high SVR rates for HCV infection in patients with and without HIV coinfection.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. (Pubmed Central) - Sep 18, 2019
The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.
- Sovaldi (sofosbuvir) / Gilead
EFFİCACY AND SAFETY OF SOFOSBUVİR BASED ANTİVİRAL THERAPY FOR CHRONİC HEPATİTİS C İNFECTİON İN PATİENTS WİTH ADVANCED CHRONİC KİDNEY DİSEASE (BEYLERBEYI HALL 2) - Sep 18, 2019 - Abstract #WCOGTSG2019WCOG_TSG_487;
In conclusion, we state that all Sofosbuvir based regimens used for the treatment of chronic hepatitis C in patients with end stage renal disease are effective as well as have low adverse effect profile making them well tolerated. A close follow up in such patients is advised especially to monitor hemoglobin levels and renal functions.
- | Sovaldi (sofosbuvir) / Gilead
Journal, IO Biomarker: Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications. (Pubmed Central) - Sep 14, 2019
A close follow up in such patients is advised especially to monitor hemoglobin levels and renal functions. The data suggest that expression of placental drug transporters and selection of antiviral drug may impact fetal drug exposure in pregnancies complicated by HCV infections.
- Sovaldi (sofosbuvir) / Gilead
Achieving Hepatitis C SVR12 of 95% in Mono-Infected Patients with Severe Comorbidities Using Volunteer Staff and Minimal Clinic Visits and Phlebotomy (204 ABC) - Sep 12, 2019 - Abstract #IDWeek2019IDWeek_860;
After initially using genotype specific therapy, we switched to pan-genotypic sofosbuvir/velapatisvir (SOF/VEL) for 12 weeks...Implementing a simplified HCV treatment program reduces patient and clinic burden and resulted in 95% achieving SVR12 despite severe comorbidities. Expansion of this program to other clinics in Wake County is underway.
- | Sovaldi (sofosbuvir) / Gilead
Le #Solvadi de @GileadSciences n’est pas efficace ? (Twitter) - Sep 12, 2019
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection. (Pubmed Central) - Sep 11, 2019
Expansion of this program to other clinics in Wake County is underway. The use of IFN-free regimens is safe and effective in the treatment of most HCV-related rheumatologic EHM.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. (Pubmed Central) - Sep 8, 2019
No serious adverse events were reported in both groups. In this real-life treatment experience, interferon-based directly acting antiviral treatment with SOF/PEG IFN/RBV as a priming for 4 weeks, followed by SOF/DCV combination for 12 weeks, led to HCV viral suppression in all treated patients.